“…This important issue can be addressed by complementing GWAS data with quantitative trait loci (QTL) datasets correlating risk genotypes with gene expression, methylation, and proteomic data (i.e., Mendelian randomization studies—MRS); this knowledge of the molecular mechanisms by which genetic variants localized in PD risk loci increase the disease risk is a key step to translating genetic evidence into possible therapeutic targets. Remarkably, the link between endolysosomal impairment and synaptic dysfunction within PD derives also from these approaches, which have recently confirmed the causal role of several “lysosomal” and “synaptic” genetic hits (i.e., ARSA , CTSB , GALC , IDUA , RAB29 , RAB7L1 , SH3GL2 , SMPD1 , STX1B , TMEM175 , VAMP42 , and ZSWIM7 ) [ 333 , 343 , 345 , 346 , 347 , 348 , 349 ].…”